U.S. Stock Market Midday Update: Anbio Biotechnology's Year-to-Date Increase Reaches 712%, Significant Capital Inflows Attract Market Attention

U.S. Stock Market Midday Update Anbio Biotechnology rose 17.61%, with a year-to-date increase of 712.00%, and no significant news recently. Trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Amgen fell 0.42%, with increased trading volume. Based on recent key news: On December 4, BMO Capital raised Amgen's target price from $335 to $372, maintaining an "Outperform" rating, indicating analysts' increased confidence in its future performance. On December 4, Amgen reported third-quarter results that exceeded expectations, mainly due to sales growth of Repatha and strong contributions from Prolia and rare disease drugs, with full-year guidance raised, leading investors to hold an optimistic view on its future growth potential. On December 3, Goldman Sachs reiterated its Buy rating on Amgen and maintained a target price of $400, anticipating key trial updates for its obesity drug MariTide, further solidifying market confidence in its long-term growth. The biotechnology industry faces drug price pressures, which need attention. Precision Science fell 0.14%. Based on recent key news: On December 2, the early cancer screening market for gastrointestinal tract in China is rapidly growing, with policy support driving market expansion. The market size is expected to achieve a compound annual growth rate of 14.4% from 2023 to 2028, providing development opportunities for related companies like Precision Science. On December 2, the project in Hanjiang District adopted multi-gene methylation technology for colorectal cancer blood testing, improving screening compliance and alleviating pressure on medical resources. This technological innovation provides possibilities for market expansion, enhancing the competitive advantage of companies like Precision Science in the molecular diagnostics field. On December 2, industry analysis pointed out that the penetration rate of molecular diagnostic technology in the early screening of colorectal cancer will rapidly increase, forming a market with greater scale effects. As a company with core technology, Precision Science will gain sustained competitive advantages in this market. The cancer early screening market is entering a golden development period. Polyrizon rose 103.80%, with a trading volume of $313 million, reaching a 60-day high, and no significant news recently. Trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Market Capitalization in the Industry AbbVie fell 0.63%. Based on recent key news: On December 2, AbbVie presented its latest data in various blood cancer treatments at the ASH 2025 conference, highlighting progress in T-cell engagers, BCL-2 inhibitors, and antibody-drug conjugates. These data show significant efficacy signals but also point out safety issues, such as neutropenia and infection risks, which may affect investor confidence On December 2nd, AbbVie announced the Phase III data of the ECLIPSE study at the 19th European Headache Congress, showing the superiority of Atogepant in the acute treatment of migraines. This result supports the efficacy of Atogepant and may have a positive impact on the stock price. On December 2nd, AbbVie announced a collaboration with Danish pharmaceutical company Gubra A/S to develop the anti-obesity compound GUB014295, entering the weight management market. This move demonstrates the company's strategic layout ahead of the patent cliff and may boost mid- to long-term financial performance. Competition in the biopharmaceutical industry is intensifying, with increased R&D investment